Aclidinium: a guide to its use in chronic obstructive pulmonary disease in the EU


    loading  Checking for direct PDF access through Ovid

Abstract

Inhaled aclidinium (Eklira® Genuair® [EU]; Bretaris® Genuair® [EU]; Tudorza™ Pressair™ [US]) is a long-acting antimuscarinic agent. In the EU, it is indicated as maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). Aclidinium provides improvements in lung function, dyspnoea and disease-specific health status in patients with COPD, and is generally well tolerated.

    loading  Loading Related Articles